NCT05378763 2026-02-18
PINNACLE
Spectrum Pharmaceuticals, Inc
Phase 3 Suspended
Clinical Trials
10 trialsNCT03318939 2024-04-03
Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
Spectrum Pharmaceuticals, Inc
Phase 2 Terminated
NCT03744715 2024-03-05
A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib
Spectrum Pharmaceuticals, Inc
Phase 2 Terminated
NCT02659514 2022-03-11
Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer
Spectrum Pharmaceuticals, Inc
Phase 2 Completed
NCT02418689 2022-01-20
Poziotinib in Patients With HER2+ Recurrent Stage IV BC Who Have Received at Least 2 Prior HER2-directed Regimens
Hanmi Pharmaceutical Company Limited
Phase 2 Completed
NCT03429101 2021-01-15
A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer
Spectrum Pharmaceuticals, Inc
Phase 1 Terminated
NCT04044170 2020-11-17
Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
Hanmi Pharmaceutical Company Limited
Phase 2 Terminated
NCT01746771 2016-03-03
A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer
Hanmi Pharmaceutical Company Limited
Phase 1/2 Completed
NCT01455571 2014-02-26
Phase I Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of HM781-36B in Patients With Advanced Solid Tumors
Hanmi Pharmaceutical Company Limited
Phase 1 Completed
NCT01455584 2013-05-23
Clinical Trial to Determine the MTD of HM781-36B in Patients With Advanced Solid Tumors
Hanmi Pharmaceutical Company Limited
Phase 1 Completed